Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Agency

All agencies FDA (Food)FDA (Drugs)FDA (Devices)USDA FSIS CPSC NHTSA EPA

6326–6350 of 8593

SevereFDA (Drugs)·D-824-2015·2015-04-29
Attix Pharmaceuticals Recalls Omeprazole Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Omeprazole Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Omeprazole Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-794-2015·2015-04-29
Attix Pharmaceuticals Recalls Metronidazole Benzoate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Metronidazole Benzoate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Metronidazole Benzoate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-956-2015·2015-04-29
Attix Pharmaceuticals Recalls Zidovudine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Zidovudine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Zidovudine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-959-2015·2015-04-29
Attix Pharmaceuticals Recalls Zolmitriptan Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling zolmitriptan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Zolmitriptan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-926-2015·2015-04-29
Attix Pharmaceuticals Recalls Thimerosal Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Thimerosal active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Thimerosal active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-677-2015·2015-04-29
Fluconazole API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Fluconazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Fluconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-686-2015·2015-04-29
Fluphenazine HCl Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Fluphenazine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Fluphenazine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-739-2015·2015-04-29
Attix Pharmaceuticals Recalls Itraconazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling itraconazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Itraconazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-583-2015·2015-04-29
Attix Pharmaceuticals Recalls Cidofovir Anhydrous Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Cidofovir Anhydrous active pharmaceutical ingredient due to a risk of penicillin cross-contamination during repackaging.
Product
Cidofovir Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-736-2015·2015-04-29
Attix Pharmaceuticals Recalls Isoproterenol Hydrochloride Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Isoproterenol Hydrochloride active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Isoproterenol Hydrochloride active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-645-2015·2015-04-29
Attix Pharmaceuticals Recalls Droperidol API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Droperidol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Droperidol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-620-2015·2015-04-29
Attix Pharmaceuticals Recalls Desmopressin Acetate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Desmopressin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Desmopressin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-604-2015·2015-04-29
Attix Pharmaceuticals Recalls Cyanocobalamin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling cyanocobalamin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Cyanocobalamin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-495-2015·2015-04-29
Attix Pharmaceuticals Recalls DMPS API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling 2,3-Dimercaptopropanesulfonic Acid Sodium Salt (DMPS) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
2,3-Dimercaptopropanesulfonic Acid Sodium Salt (DMPS) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-740-2015·2015-04-29
Kanamycin Sulfate Recalled Due to Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Kanamycin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Kanamycin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-718-2015·2015-04-29
Attix Pharmaceuticals Recalls Hydroxocobalamin Acetate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydroxocobalamin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydroxocobalamin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-832-2015·2015-04-29
Attix Pharmaceuticals Recalls Paromomycin Sulphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Paromomycin Sulphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Paromomycin Sulphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-499-2015·2015-04-29
Acetazolamide API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Acetazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Acetazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-0969-2015·2015-04-29
Hospira Recalls 0.9% Sodium Chloride Injection Due to Human Hair Particulate
Hospira is recalling 0.9% Sodium Chloride Injection, USP, 250 mL, because a human hair was found sealed in the bag at the additive port area.
Product
0.9% Sodium Chloride Injection, USP, 250 mL, Rx Only, Hospira Inc., Lake Forest, IL, 60045, USA, NDC 0409-7983-02
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-766-2015·2015-04-29
Attix Pharmaceuticals Recalls Lisinopril Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Lisinopril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Lisinopril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-851-2015·2015-04-29
Attix Pharmaceuticals Recalls Potassium Phosphate Monobasic Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Potassium Phosphate Monobasic distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Potassium Phosphate Monobasic pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-911-2015·2015-04-29
Attix Pharmaceuticals Recalls Tadalafil API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tadalafil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tadalafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-947-2015·2015-04-29
Attix Pharmaceuticals Recalls Ursodiol API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Ursodiol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Ursodiol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-531-2015·2015-04-29
Attix Pharmaceuticals Recalls Azatadine Maleate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Azatadine Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Azatadine Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide
SevereFDA (Drugs)·D-944-2015·2015-04-29
Attix Pharmaceuticals Recalls Trifluridine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Trifluridine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Trifluridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Drug
Distribution
Distributed nationwide

How to read this listing

Filters

6326–6350 of 8593